Acadia Pharmaceuticals | ACAD - Cost Of Sales


Acadia Pharmaceuticals reported $24.79M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
Eisai JPY 52.02B 931M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
J&J USD 8.07B 103M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Prothena USD 28.94M 11.58M Sep/2025
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026